- Home
- ENLT vs CDTX Comparison
ENLT vs CDTX Comparison
Compare ENLT & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- CDTX
- Stock Information
- Founded
- ENLT 2008
- CDTX 2012
- Country
- ENLT Israel
- CDTX United States
- Employees
- ENLT N/A
- CDTX N/A
- Industry
- ENLT
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENLT
- CDTX Health Care
- Exchange
- ENLT Nasdaq
- CDTX Nasdaq
- Market Cap
- ENLT 2.9B
- CDTX 2.8B
- IPO Year
- ENLT 2023
- CDTX 2015
- Fundamental
- Price
- ENLT $36.00
- CDTX $101.72
- Analyst Decision
- ENLT Hold
- CDTX Strong Buy
- Analyst Count
- ENLT 4
- CDTX 13
- Target Price
- ENLT $28.50
- CDTX $118.50
- AVG Volume (30 Days)
- ENLT 28.5K
- CDTX 938.8K
- Earning Date
- ENLT 11-12-2025
- CDTX 11-06-2025
- Dividend Yield
- ENLT N/A
- CDTX N/A
- EPS Growth
- ENLT N/A
- CDTX N/A
- EPS
- ENLT 0.17
- CDTX N/A
- Revenue
- ENLT $428,715,000.00
- CDTX N/A
- Revenue This Year
- ENLT $355.90
- CDTX N/A
- Revenue Next Year
- ENLT $42.83
- CDTX N/A
- P/E Ratio
- ENLT $213.01
- CDTX N/A
- Revenue Growth
- ENLT 39.54
- CDTX N/A
- 52 Week Low
- ENLT $14.01
- CDTX $12.74
- 52 Week High
- ENLT $36.65
- CDTX $121.21
- Technical
- Relative Strength Index (RSI)
- ENLT 66.39
- CDTX 54.83
- Support Level
- ENLT $34.42
- CDTX $102.19
- Resistance Level
- ENLT $36.01
- CDTX $113.00
- Average True Range (ATR)
- ENLT 0.86
- CDTX 6.48
- MACD
- ENLT -0.08
- CDTX -0.89
- Stochastic Oscillator
- ENLT 76.92
- CDTX 47.27
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.